Research Workshop Program
We are delighted to invite you to the 2024 GESA Research Workshop in South Australia. Join us before AGW 2024 to explore the theme of Food. Mood. Energy.
Key Highlights:
Focus: Explore the multidisciplinary nature of gastroenterology research.
Target Audience: Experts in different fields of GI research, clinical and translational researchers from all career stages.
Opportunity: Listen, learn, present, network and collaborate within a relaxed and supportive environment.
Speakers: Enjoy talks from invited international and national speakers along with short talks selected from submitted abstracts.
Dates: Wednesday 11- Friday 13 September 2024
Locations: 11-12 September
Stamford Grand Adelaide Hotel
2 Jetty Road Glenelg SA
13 September
Adelaide Convention Centre - AGW venue
Panorama Room 2
Wednesday Sept 11 Program
| Time | Session | Speakers |
|---|---|---|
| 12:00 | Registration and Lunch | |
| 14:00 | Welcome and Acknowledgement of Country | Welcome Chair: Georgina Hold |
| 14:10 | Invited Speaker - Advanced Imaging and AI in Enabling Precision Medicine in Intestinal Disease | Marietta Iacucci (Ireland) |
| Session 1 - Lower GI Cancer | Co-Chairs: Susi Woods and Lochlan Fennell | |
| 14:45 | Colorectal cancer - from benchtop to bedside | Ryash Vather |
| 15:05 | Distal colonic crypt hyperplasia is not adversely impacted by Emu Oil and Saireito in a murine model of colitis-associated colorectal cancer | Suzanne Mashtoub |
| 15:15 | Exploring the microbiome of the faecal immunochemical test for improved colorectal cancer screening | Geraldine Laven-Law |
| 15:20 | Investigating the role of E. coli Nissle biofilm formation in colorectal cancer tumour colonisation | Rebekah de Nys |
| 15:25 | Butyrate impacts polyp initiation in familial adenomatous polyposis: results of a randomised, double-blind, placebo-controlled crossover trial | Finaly Macrae |
| 15:35 | Participation, positivity and polyps: bowel cancer screening in people aged 40 to 49 years | Erin Symonds |
| 15:40 | Question and Discussion | |
| 15:45 | Characterising the role of the tumour microenvironment in colorectal cancer | Thierry Jarde |
| 16:05 | Afternoon Tea | |
| Session 2 - Upper GI Cancer | Co-Chairs: Georgina Hold and Rebeka de Nys | |
| 16:30 | Defining new molecular pathways in Helicobacter-induced gastric MALT lymphoma | Richard Ferrero |
| 16:50 | A new ctDNA blood biomarker test to detect and monitor pancreatic adenocarcinoma in response to therapy | Jean Winter |
| 16:55 | Exploring the biomarker potential of circulating small extracellular vesicles in pancreatic cancer | Arunima Panda |
| 17:00 | Effects of exosomes derived from pancreatic cancer and stellate co-cultures on insulin signalling pathway factors: Potential mediators of pancreatic cancer-related diabetes | Chamini Perera |
| 17:05 | The Epidemiology of Hereditary Pancreatitis Patients in Australia and Total Pancreatectomy With Islet Autologous Transplantation Outcomes | Denghao Wu |
| 17:10 | Patient-derived organoid culture: Advancing personalized chemotherapy for gastrointestinal peritoneal metastases | Harleen Kaur |
| 17:15 | Characterising peritoneal macrophage responses to infection in patients with cirrhotic ascites | Scott Read |
| 17:20 | Questions and Discussion | |
| 17:30 | Immunological predictors of outcome in gastric cancer | Alex Boussioutas |
| Session 3 - Abstracts of Merit | Chair: Kate Irvine | |
| 17:50 | Impaired health-related quality of life is associated with alterations in gut microbiota in patients with inflammatory bowel disease: baseline sequencing from the Australian IBD Microbiome study | Thisun Jayawardana |
| 18:05 | Transcriptomic analysis of exosome cargo derived from pancreatic cancer and stellate cells: prospective mediators of pancreatic cancer-related diabetes | Helen Binang |
| 18:20 | Impact of gut microbiota on immune modulation and response to immune checkpoint inhibitors in hepatocellular carcinoma: insights from human and preclinical models | Jayashi Rajapakse |
| 18:35 | Closing Remarks | |
| 19:00 | Networking Event - Slow Food |
Thursday Sept 12 Program
| Time | Session | Speakers |
|---|---|---|
| 08:30 | Welcome to Day Two | Chair: Mark Morrison |
| 08:35 | Food as Medicine: Therapeutic Diets for Gut Health | Emma Halmos |
| Session 4 - Gastroenterology and Hepatology Abstracts | Co Chairs: Kylie James and Rabina Giri | |
| 09:10 | Research in the Disorders of Gut-Brain interaction: What scientist and clinician need to know | Gerald Holtmann |
| 09:30 | Effect of feeding a minimally processed cooked diet versus an ultra-processed kibble diet on the gut microbiome and physiology of healthy domestic dogs | Louise Campbell |
| 09:35 | Integrating Biology and Psychology - the My Diet Study: Risk-Benefit Assessment of Self-Directed Dieting in Young Adults. | Mirei Okada |
| 09:40 | Effects of the very low energy diet compared to a Mediterranean diet on hepatic and metabolic outcomes in metabolic associated steatotic liver disease: A randomised control trial | Alex Thompson |
| 09:45 | The duodenal mucosa-associated microbiota differs in patients based on their Rome IV classification, and has variable effects on duodenal spheroid barrier function subjects | Lauren Schooth |
| 09:50 | Spatial transcriptomics of daHep enriched regions in pre-malignant human liver tissue: enhancing early detection and risk stratification for hepatocellular carcinoma | Anjali Ghimire |
| 09:55 | Integrative machine learning model using multi-omics data for early prediction and biomarker identification of hepatocellular carcinoma | Annette Spooner |
| 10:00 | Endothelial compartment expression of prostate-specific membrane antigen (PSMA) accurately discriminates hepatocellular carcinoma (HCC) from benign tissue | Nicholas Hannah |
| 10:05 | A double-blind, placebo-controlled, adaptive dose-response study to assess the acute effects of micro-doses of gluten in adults with treated coeliac disease (Gluten Threshold Study). | James Daveson |
| 10:10 | Colonic dysmotility associated with Disorders of Gut-Brain Interaction | Phil Dinning |
| 10:30 | Morning Tea | |
| Session 5 - Liver Disease | Co Chairs: Christian Nefzger and Scott Read | |
| 11:00 | Pushing the boundaries in liver cancer research to advance personalised treatment | Nina Tirnitz-Parker |
| 11:20 | Remaining chronic hepatitis C treatment gaps impact on the care cascade of HCV related hepatocellular carcinoma | Jessica Howell |
| 11:30 | Antigen specific natural killer cells hold promise as a novel cell therapy targeting hepatitis B virus | Dishen Corey Cohen |
| 11:35 | The anti-fibrotic therapeutic potential of a proprietary microRNA-25 mimic for chronic liver disease | Brianna Pollock |
| 11:40 | Therapeutic potential of Ellagic acid on a NASH mouse model | Tharani Senavirathna |
| 11:45 | Identification and characterisation of a novel gene variant associated with steatotic liver disease | Gary Huang |
| 11:50 | Macrophage therapeutic potential in metabolic dysfunction associated fatty liver disease | Sahar Keshvari |
| 11:55 | Investigating the role of soluble PD-L1 in immunotherapy response in Hepatocellular Carcinoma patients receiving anti-PD-L1 treatment | William Chambers |
| 12:00 | Genomic and epigenomic profiling of circulating tumour DNA in hepatocelullar carcinoma | Lauren Andersson |
| 12:05 | Lean MAFLD: Does it exist? Understanding the phenotype | Jacob George |
| 12:20 | Lunch | |
| Session 6 - IBD | Co-Chairs: Nina Tirnitz-Parker and Thisun Jayawardana | |
| 13:30 | Defining the PSC-UC and UC colonic mucosa with paired microbial and single-cell RNA sequencing | Kylie James |
| 13:50 | A novel and rapid faecal myeloperoxidase assay predicts endoscopic findings in patients with IBD | Belal Chami |
| 13:55 | Unique faecal microbial profiles in first degree relatives of inflammatory bowel disease patientss | Sabrina Koentgen |
| 14:00 | Allosteric Modulation of Cannabinoid 1 Receptor as a Novel Therapeutic Strategy for Inflammatory Bowel Disease | Dinesh Thapa |
| 14:05 | Topical upadacitinib is effective in distal Ulcerative colitis - A case study and pre-clinical proof of concept | Rabina Giri |
| 14:10 | Antigen-specific regulatory T cell therapy for inflammatory bowel disease | Rimma Goldberg |
| 14:15 | Longitudinal microbial dynamics in an Australian adult inflammatory bowel disease cohort | Yashar Houshyar |
| 14:20 | Classification methods for ultra-processed food intake show higher intake in patients with irritable bowel syndrome compared to healthy volunteers | Chu Yao |
| 14:25 | Questions and Discussion | |
| 14:30 | Deciphering the immunomodulatory function of the microbiome in IBD | Jake Begun |
| 14:50 | Afternoon Tea | |
| Session 7 - Talks | Chair: Katharine Irvine | |
| 15:20 | Decoding age-related alterations in liver transcription factor networks and zonation through spatial transcriptomics | Christian Nefzger |
| 15:40 | Clinical trials in the GI space – the scientists’ role | Nick Powell (UK) |
| 16:05 | Globe trekking to reach your goal – what makes a successful clinical research career | Nick Talley |
| 16:35 | Closing Remarks | |
| 19:00 | Evening Program - Sit-Down Dinner |
Friday Sept 13 Program
| Time | Session | Speakers |
|---|---|---|
| 12:30 | Lunch | |
| 13:30 | Introduction | Chair: Georgina Hold |
| 13:35 | Microbiome Therapeutics in Liver Disease | Jasmohan Bajaj (US) |
| Session 8 - Microbiome | Co Chairs: Georgina Hold and Kate Irvine | |
| 14:05 | Site and strain-specific analysis of the IBD microbiome | Ed Giles |
| 14:25 | Deep functional analysis of a defined sulphide-reducing diet (4-SURE diet) as a novel therapy for ulcerative colitis (UC) demonstrates all specific luminal micro environmental objectives were achieved | Alice Day |
| 14:30 | Microbial signatures associated with inflammatory bowel disease in Australia: baseline sequencing from the Australian IBD Microbiome study | Thisun Jayawardana |
| 14:35 | The biogeograghy of the mucosa-associated microbiota is associated with the presence and symptom severity of inflammatory bowel disease, proton pump inhibitor usage, and visceral sensitivity | Mark Morrison |
| 14:40 | Multiomic modelling of antibiotic perturbed faecal microbial communities demonstrates reduced microbial resilience in Inflammatory Bowel Disease | Sabrina Koentgen |
| 14:45 | The UC phenotype of a rare mutation in OTUD3 is exacerbated by high fat or high fructose diets in an experimental mouse model | Rabina Giri |
| 14:50 | Therapeutic potential of inulin-coated medium-chain triglyceride microcapsules for effective treatment of metabolic and inflammatory outcomes in diet-induced disease | Amin Ariaee |
| 14:55 | Hepatic steatosis in young adults is associated with altered gut microbiology | Yasmina Tashkent |
| 15:00 | Microbial-Metabolite interactions in MAFLD cirrhosis: Insights from MiMeNet-driven metagenomic and metabolomic integration | Mohamed Moridani |
| 15:05 | The tumour microenvironment influences checkpoint expression by gamma delta T cell subpopulations in hepatocellular carcinoma | Paul Armstrong |
| 15:10 | An early review of MetaPanel™ - a diagnostic metagenomic gastrointestinal pathogen assay | Michael Wehrhahn |
| 15:15 | Bringing the mucosa-associated microbiome to life to advance digestive health | Mark Morrison |
| 15:40 | Get Your Message Out - How to Navigate the Publishing Journey | Emad El-Omar |
| 16:10 | Closing Remarks | Kate Irvine and Georgina Hold |
| End of AGW 2024 Research Workshop |